{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:47Z","timestamp":1790286947119,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40264-021-01071-1","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T17:02:40Z","timestamp":1620320560000},"page":"725-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4\/6 Inhibitors: A Systematic Review"],"prefix":"10.1007","volume":"44","author":[{"given":"Martina","family":"Silvestri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cristaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Bennardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Paul","family":"Nistic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7964-3388","authenticated-orcid":false,"given":"Maria","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"issue":"10226","key":"1071_CR1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(20)30165-3.","journal-title":"Lancet"},{"issue":"1","key":"1071_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","volume":"18","author":"RS Finn","year":"2016","unstructured":"Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;18(1):17. https:\/\/doi.org\/10.1186\/s13058-015-0661-5.","journal-title":"Breast Cancer Res"},{"key":"1071_CR3","doi-asserted-by":"publisher","unstructured":"Turner NC, Ro J, Andr\u00e9 F, Loi S, Verma S, Iwata H, et al.; PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209\u201319. https:\/\/doi.org\/10.1056\/nejmoa1505270.","DOI":"10.1056\/nejmoa1505270"},{"key":"1071_CR4","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"G Hortobagyi","year":"2016","unstructured":"Hortobagyi G, Stemmer S, Burris H, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","journal-title":"N Engl J Med"},{"key":"1071_CR5","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR\u2009+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875\u201384. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1071_CR6","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"3","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018;3(10):1758835918793326. https:\/\/doi.org\/10.1177\/1758835918793326.","journal-title":"Ther Adv Med Oncol."},{"key":"1071_CR7","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1810527.","journal-title":"N Engl J Med"},{"key":"1071_CR8","unstructured":"Lam SY, Liu WS, Lee C-S. A review of CDK4\/6 inhibitors. U.S. Pharmacist. 2020;45(Suppl 5):3\u20138."},{"issue":"9","key":"1071_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/14737140.2017.1355242","volume":"17","author":"S Lasheen","year":"2017","unstructured":"Lasheen S, Shohdy KS, Kassem L, Abdel-Rahman O. Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Expert Rev Anticancer Ther. 2017;17(9):851\u20136. https:\/\/doi.org\/10.1080\/14737140.2017.1355242.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"1071_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","volume":"18","author":"V Saggar","year":"2013","unstructured":"Saggar V, Wu S, Dickler MN, Lacouture ME. Alopecia with endocrine therapies in patients with cancer. Oncologist. 2013;18(10):1126\u201334. https:\/\/doi.org\/10.1634\/theoncologist.2013-0193.","journal-title":"Oncologist."},{"issue":"6","key":"1071_CR11","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","volume":"154","author":"A Freites-Martinez","year":"2018","unstructured":"Freites-Martinez A, Shapiro J, Chan D, et al. Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. 2018;154(6):670\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2018.0454.","journal-title":"JAMA Dermatol."},{"issue":"6","key":"1071_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/0284186X.2020.1738547","volume":"59","author":"D Eiger","year":"2020","unstructured":"Eiger D, Wagner M, Pond\u00e9 NF, Nogueira MS, Buisseret L, de Azambuja E. The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4\/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). Acta Oncol. 2020;59(6):723\u20135. https:\/\/doi.org\/10.1080\/0284186X.2020.1738547.","journal-title":"Acta Oncol"},{"key":"1071_CR13","doi-asserted-by":"publisher","unstructured":"Chan D, Freites Martinez AD, Goldfarb SB, et al. CDK4\/6 plus aromatase inhibitor-induced alopecia in breast cancer patients. J Clin Oncol. 2019;37(15_Suppl):e12537. https:\/\/doi.org\/10.1200\/jco.2019.37.15_suppl.e12537.","DOI":"10.1200\/jco.2019.37.15_suppl.e12537"},{"issue":"1","key":"1071_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12748","volume":"32","author":"C Palleria","year":"2019","unstructured":"Palleria C, Bennardo L, Dastoli S, Iannone LF, Silvestri M, Manti A, et al. Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: a case series and literature review. Dermatol Ther. 2019;32(1): https:\/\/doi.org\/10.1111\/dth.12748.","journal-title":"Dermatol Ther"},{"issue":"9","key":"1071_CR15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10229","volume":"12","author":"NAJ Khan","year":"2020","unstructured":"Khan NAJ, Alsharedi M. Bullous skin rash: a rare case of palbociclib-induced dermatological toxicity. Cureus. 2020;12(9): https:\/\/doi.org\/10.7759\/cureus.10229.","journal-title":"Cureus."},{"key":"1071_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jdcr.2017.12.015","volume":"4","author":"T Karagounis","year":"2018","unstructured":"Karagounis T, Vallurupalli M, Nathan N, Nazarian R, Vedak P, Spring L, et al. Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer. JAAD Case Rep. 2018;4:452\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2017.12.015.","journal-title":"JAAD Case Rep."},{"issue":"4","key":"1071_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.4048\/jbc.2019.22.e44","volume":"22","author":"V L\u00f3pez-G\u00f3mez","year":"2019","unstructured":"L\u00f3pez-G\u00f3mez V, Yarza R, Mu\u00f1oz-Gonz\u00e1lez H, Revilla E, Enrech S, Gonz\u00e1lez-Valle O, et al. Ribociclib-related Stevens-Johnson syndrome: oncologic awareness, case report, and literature review. J Breast Cancer. 2019;22(4):661\u20136. https:\/\/doi.org\/10.4048\/jbc.2019.22.e44.","journal-title":"J Breast Cancer."},{"issue":"7","key":"1071_CR18","doi-asserted-by":"publisher","first-page":"1325.e3","DOI":"10.1016\/j.ajem.2018.04.019","volume":"36","author":"S Widmer","year":"2018","unstructured":"Widmer S, Grossman M. Chemotherapy patient with Stevens-Johnson syndrome presents to the emergency department: a case report. Am J Emerg Med. 2018;36(7):1325.e3\u20134. https:\/\/doi.org\/10.1016\/j.ajem.2018.04.019.","journal-title":"Am J Emerg Med"},{"issue":"4","key":"1071_CR19","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/tbj.13570","volume":"26","author":"Y Bozkaya","year":"2020","unstructured":"Bozkaya Y, Ay B. Toxic epidermal necrolysis associated with ribociclib in a patient with metastatic breast cancer. Breast J. 2020;26(4):773\u20134. https:\/\/doi.org\/10.1111\/tbj.13570.","journal-title":"Breast J."},{"key":"1071_CR20","unstructured":"Oakley AM, Krishnamurthy K. Stevens Johnson syndrome. 20 Nov 2020. Treasure Island (FL): StatPearls Publishing; 2020."},{"issue":"1","key":"1071_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3747\/co.2008.201","volume":"15","author":"AE Hird","year":"2008","unstructured":"Hird AE, Wilson J, Symons S, Sinclair E, Davis M, Chow E. Radiation recall dermatitis: case report and review of the literature. Curr Oncol. 2008;15(1):53\u201362. https:\/\/doi.org\/10.3747\/co.2008.201.","journal-title":"Curr Oncol."},{"issue":"20","key":"1071_CR22","doi-asserted-by":"publisher","first-page":"30051","DOI":"10.1016\/j.hemonc.2020.04.005","volume":"S1658\u20133876","author":"A Erjan","year":"2020","unstructured":"Erjan A, Dayyat A. Ribociclib-induced radiation recall dermatitis following stereotactic body radiation therapy: case report and literature review. Hematol Oncol Stem Cell Ther. 2020;S1658\u20133876(20):30051. https:\/\/doi.org\/10.1016\/j.hemonc.2020.04.005.","journal-title":"Hematol Oncol Stem Cell Ther."},{"issue":"3","key":"1071_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.rpor.2019.03.001","volume":"24","author":"JA Messer","year":"2019","unstructured":"Messer JA, Ekinci E, Patel TA, Teh BS. Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: a case report. Rep Pract Oncol Radiother. 2019;24(3):276\u201380. https:\/\/doi.org\/10.1016\/j.rpor.2019.03.001.","journal-title":"Rep Pract Oncol Radiother."},{"key":"1071_CR24","doi-asserted-by":"publisher","unstructured":"Lee C-L, Oh P, Xu ES. Blocking cyclin-dependent kinase 4\/6 during single dose vs. fractionated radiation therapy leads to opposite effects on acute gastrointestinal toxicity in mice. Int J Radiat Oncol Biol Phys. 2018;102(5):1569\u201376. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.192.","DOI":"10.1016\/j.ijrobp.2018.07.192"},{"issue":"5","key":"1071_CR25","doi-asserted-by":"publisher","first-page":"e755","DOI":"10.1016\/j.clbc.2018.07.006","volume":"18","author":"S Guillemois","year":"2018","unstructured":"Guillemois S, Patsouris A, Peyraga G, Chassain K, Le Corre Y, Campone M, et al. Cutaneous and gastrointestinal leukocytoclastic vasculitis induced by palbociclib in a metastatic breast cancer patient: a case report. Clin Breast Cancer. 2018;18(5):e755\u20138. https:\/\/doi.org\/10.1016\/j.clbc.2018.07.006.","journal-title":"Clin Breast Cancer."},{"key":"1071_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.breast.2020.05.011","volume":"52","author":"C Omarini","year":"2020","unstructured":"Omarini C, Molinaro E, Barbolini M, Dominici M, Piacentini F. Henoch-sch\u00f6nlein purpura (HSP) in a patient on abemaciclib. Breast. 2020;52:132\u20133. https:\/\/doi.org\/10.1016\/j.breast.2020.05.011.","journal-title":"Breast"},{"key":"1071_CR27","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","volume":"22","author":"DA Schaer","year":"2018","unstructured":"Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N. The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22:2978\u201394. https:\/\/doi.org\/10.1016\/j.celrep.2018.02.053.","journal-title":"Cell Rep."},{"issue":"2","key":"1071_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1590\/s1807-59322008000200018","volume":"63","author":"MJ L\u00f3pez Meiller","year":"2008","unstructured":"L\u00f3pez Meiller MJ, Cavallasca JA, Maliandi Mdel R, Nasswetter GG. Henoch-Sch\u00f6nlein purpura in adults. Clinics (Sao Paulo). 2008;63(2):273\u20136. https:\/\/doi.org\/10.1590\/s1807-59322008000200018.","journal-title":"Clinics (Sao Paulo)."},{"key":"1071_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4067\/S0370-41062018000100103","volume":"89","author":"T Hasbun","year":"2018","unstructured":"Hasbun T, Chaparro X, Kaplan V, Cavagnaro F, Castro A. Bullous henoch-schonlein purpura: case report. Rev Chil Pediatr. 2018;89:103\u20136. https:\/\/doi.org\/10.4067\/S0370-41062018000100103.","journal-title":"Rev Chil Pediatr."},{"issue":"5","key":"1071_CR30","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/BOR.0000000000000522","volume":"30","author":"Y He","year":"2018","unstructured":"He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018;30(5):490\u20137. https:\/\/doi.org\/10.1097\/BOR.0000000000000522.","journal-title":"Curr Opin Rheumatol"},{"key":"1071_CR31","doi-asserted-by":"publisher","unstructured":"Pinard J, Patel M, Granter SR, Vleugels RA, Merola JF. Subacute cutaneous lupus erythematosus induced by palbociclib. J Cutan Med Surg. 2018;22(3):341\u20133. https:\/\/doi.org\/10.1177\/1203475417752369.","DOI":"10.1177\/1203475417752369"},{"issue":"7","key":"1071_CR32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cup.13673","volume":"47","author":"E Russell-Goldman","year":"2020","unstructured":"Russell-Goldman E, Nazarian RM. Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: a case report and literature review. J Cutan Pathol. 2020;47(7):654\u20138. https:\/\/doi.org\/10.1111\/cup.13673.","journal-title":"J Cutan Pathol"},{"issue":"9","key":"1071_CR33","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jamadermatol.2013.4957","volume":"149","author":"LE Wiznia","year":"2013","unstructured":"Wiznia LE, Subtil A, Choi JN. Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol. 2013;149(9):1071\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2013.4957.","journal-title":"JAMA Dermatol."},{"issue":"12","key":"1071_CR34","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.1610-0387.2012.08000.x","volume":"10","author":"C Dalle Vedove","year":"2012","unstructured":"Dalle Vedove C, Simon JC, Girolomoni G. Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF\u03b1 agents. J Dtsch Dermatol Ges. 2012;10(12):889\u201397. https:\/\/doi.org\/10.1111\/j.1610-0387.2012.08000.x.","journal-title":"J Dtsch Dermatol Ges."},{"issue":"6","key":"1071_CR35","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1111\/ijd.14716","volume":"59","author":"JB Freedman","year":"2020","unstructured":"Freedman JB, Herskovitz I, Maderal AD. Chronic cutaneous lupus erythematosus (discoid lupus) induced by palbociclib. Int J Dermatol. 2020;59(6):e216\u20138. https:\/\/doi.org\/10.1111\/ijd.14716.","journal-title":"Int J Dermatol"},{"issue":"7","key":"1071_CR36","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/cup.13696","volume":"47","author":"G Calabrese","year":"2020","unstructured":"Calabrese G, Licata G, Gambardella A, De Rosa A, Ronchi A, Argenziano G. A case of discoid lupus erythematosus because of palbociclib. J Cutan Pathol. 2020;47(7):668\u201370. https:\/\/doi.org\/10.1111\/cup.13696.","journal-title":"J Cutan Pathol"},{"key":"1071_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng J, Wang ES, Jenkins RW, et al. CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8:216\u201333. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0915.","journal-title":"Cancer Discov"},{"issue":"2","key":"1071_CR38","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/ced.14361","volume":"46","author":"X Fust\u00e0-Novell","year":"2021","unstructured":"Fust\u00e0-Novell X, Morgado-Carrasco D, Garc\u00eda-Herrera A, Bosch-Amate X, Mart\u00ed-Mart\u00ed I, Carrera C. Palbociclib-induced histiocytoid Sweet syndrome. Clin Exp Dermatol. 2021;46(2):348\u201350. https:\/\/doi.org\/10.1111\/ced.14361.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1071_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1365-2230.2005.01996.x","volume":"31","author":"JM White","year":"2006","unstructured":"White JM, Mufti GJ, Salisbury JR, du Vivier AW. Cutaneous manifestations of granulocyte colony-stimulating factor. Clin Exp Dermatol. 2006;31(2):206\u20137. https:\/\/doi.org\/10.1111\/j.1365-2230.2005.01996.x.","journal-title":"Clin Exp Dermatol"},{"key":"1071_CR40","doi-asserted-by":"publisher","unstructured":"Sollena P, Nikolaou V, Soupos N, Kotteas E, Voudouri D, Stratigos AJ, et al.; European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Res Treat. 2021;185(1):247\u201353. https:\/\/doi.org\/10.1007\/s10549-020-05914-w.","DOI":"10.1007\/s10549-020-05914-w"},{"issue":"3","key":"1071_CR41","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.3892\/mmr.2018.9299","volume":"18","author":"M Zhou","year":"2018","unstructured":"Zhou M, Lin F, Xu W, Jin R, Xu A. Decreased SUMOylation of the retinoblastoma protein in keratinocytes during the pathogenesis of vitiligo. Mol Med Rep. 2018;18(3):3469\u201375. https:\/\/doi.org\/10.3892\/mmr.2018.9299.","journal-title":"Mol Med Rep."},{"issue":"5","key":"1071_CR42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1089\/pho.2015.4004","volume":"34","author":"G Babino","year":"2016","unstructured":"Babino G, Giunta A, Esposito M, Saraceno R, Pavlidis A, Del Duca E, et al. UVA1 laser in the treatment of vitiligo. Photomed Laser Surg. 2016;34(5):200\u20134. https:\/\/doi.org\/10.1089\/pho.2015.4004.","journal-title":"Photomed Laser Surg."},{"issue":"4","key":"1071_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijwd.2018.08.003","volume":"4","author":"N Leung","year":"2018","unstructured":"Leung N, Oliveira M, Selim MA, McKinley-Grant L, Lesesky E. Erythema dyschromicum perstans: a case report and systematic review of histologic presentation and treatment. Int J Womens Dermatol. 2018;4(4):216\u201322. https:\/\/doi.org\/10.1016\/j.ijwd.2018.08.003.","journal-title":"Int J Womens Dermatol."},{"issue":"1","key":"1071_CR44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4048\/jbc.2021.24.e1","volume":"24","author":"M Mariano","year":"2021","unstructured":"Mariano M, Donati P, Cameli N, Pigliacelli F, Morrone A, Cristaudo A. Ribociclib-induced erythema dyschromicum perstans (ashy dermatosis)-like pigmentation in a metastatic breast cancer patient. J Breast Cancer. 2021;24(1):117\u201321. https:\/\/doi.org\/10.4048\/jbc.2021.24.e1.","journal-title":"J Breast Cancer."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01071-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01071-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01071-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T08:23:27Z","timestamp":1624263807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01071-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1071"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01071-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"15 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was received for the conduct of this research or the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Martina Silvestri, Antonio Cristaudo, Aldo Morrone, Claudia Messina, Luigi Bennardo, Steven Paul Nistic\u00f2, Maria Mariano, and Norma Cameli have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MS: study design; conceptualization; methodology; writing original draft; databases strategy research and extraction of data. AC: conceptualization; supervision; data curation. AM: critical revision of the manuscript. CM: databases strategy research. LB: data curation; SPN: supervision, data curation. MM: conceptualization; methodology; data curation. NC: study design; conceptualization; methodology; supervision; data curation. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}